Top Injectable Manufacturer in Sri Lanka – Reliable Pharmaceutical Solutions
- Maulik Sudani
- Jul 27
- 11 min read
Last Updated: July 27, 2026
TL;DR: Sri Lanka is a market of roughly 23.2 million people where the state sector delivers about 95% of inpatient care through 1,209 government health institutions and 90,392 beds, and where India already supplies half of everything on the register. As at 23 July 2026, 3,291 of 6,577 valid NMRA registrations were Indian-made, including 700 of 1,255 injectable registrations. The regulator is the National Medicines Regulatory Authority (NMRA), constituted under the NMRA Act No. 5 of 2015; registration runs five years and the GL-025 reliance route clears a qualifying dossier in 90 days. Two rules decide whether an entry works: since 1 January 2025 NMRA accepts foreign manufacturing-site applications only from PIC/S, EU GMP, WHO-prequalified or WHO-inspected plants, and your margin is capped by a gazetted maximum retail price formula that benchmarks your declared CIF against India's own NPPA prices. Farbe Firma Pvt Ltd manufactures over 100 sterile injectables at a WHO-GMP certified, ISO Class 5 facility in Gujarat, India, exports to more than 30 countries, and prepares CTD/ACTD dossiers, WHO-format CPPs and NMRA-compliant artwork.
Key Takeaways
Settle site eligibility before you write a dossier. Since 1 January 2025 the NMRA accepts foreign manufacturing-site applications only from sites holding PIC/S approval, EU GMP approval, or WHO prequalification or WHO-team inspection; anything outside those categories is considered case by case by the CEO on the recommendation of the Manufacturing Peer Review Committee. Foreign premises approval is billed at US$2,000, and a foreign GMP inspection is charged to SAARC applicants at US$15,000 plus airfare and visas. Establishing eligibility is step one, not step three.
Reliance is the fast lane. The GL-025 Reliance Practices guideline, effective 31 January 2025, registers a qualifying product in 90 days, and a WHO-prequalified or CEP-covered active substance lets the applicant skip the drug-substance part of Module 3 entirely. Sri Lanka has also participated in the WHO Collaborative Registration Procedure since 2017, again on a 90-day clock. India's CDSCO is not an NMRA reference authority, so build the reliance case on WHO prequalification or an ICH-authority approval rather than on a domestic Indian approval.
Price, not tariff, is the commercial gate. Under Gazette 2446/34 of 21 July 2025 and GL-033 v1.1, the maximum retail price is CIF plus duties and taxes plus a single blended supply-chain and trade margin that slides from 75% where CIF is under LKR 40 down to 45% where CIF is LKR 6,500 or more. NMRA verifies the declared CIF against India's NPPA prices as well as Bangladesh, Pakistan and international references, MRPs for 350 medicines were published on 17 November 2025, and a currency movement above 5% is the only revision trigger.
Zero at the border, slow through the gate. Registered medicines enter free of general customs duty and exempt from VAT, PAL and SSCL, and stayed exempt when standard VAT rose to 20.5% on 1 July 2026. But Sri Lanka Customs' 2025 Time Release Study puts NMRA-referred sea consignments at a median 74 hours 58 minutes against 51 hours 32 minutes overall, and every commercial pack released from 1 April 2026 must carry the words “NMRA Registered Product” with the approved MRP, plus a product-specific QR code or 2D DataMatrix.
Introduction: Why an Injectable Manufacturer in Sri Lanka Must Meet Global Standards
Sri Lanka runs one of the most institutionally dense public health systems in South Asia: 1,209 government health institutions, 90,392 beds, roughly seven million admissions and 55 million outpatient visits a year, with the state sector carrying about 95% of inpatient care. Almost none of the injectable volume that system consumes is made locally. Only four sterile plants hold local manufacturing approval — Kelun at Pallekele, Navesta, Sands Active and Yaden — and between them they account for just 103 injectable registrations, about 60% of them Kelun's. The State Pharmaceuticals Manufacturing Corporation, the state-owned manufacturer, has no injectable line at all; its approved scope is general and penicillin oral solid dosage forms, and its 2024 output was 3.17 billion tablets and capsules. Any injectable manufacturer in Sri Lanka worth engaging is therefore, by arithmetic, an importer's partner rather than a domestic competitor.
The demand behind that structure is heavy and currently rising. Sri Lanka is having a record dengue year: 56,422 cases were reported by 1 July 2026, already above the full-year 2025 total, which drives crystalloid and fluid-resuscitation volume through every base and district general hospital. Leptospirosis killed 203 people in 2023, more than three times the dengue toll that year. Septicaemia recorded 18,955 admissions and 8,762 deaths at a 46.2% case-fatality rate in 2023, which is an injectable anti-infective problem before it is anything else. Around 200,000 institutional deliveries take place annually at a caesarean rate near 42%, pulling oxytocin, tranexamic acid, magnesium sulphate and anaesthesia lines. Snakebite produced 29,975 hospital admissions in 2023 against zero domestic antivenom production and an antivenom bill of about US$6.3 million a year. Non-communicable disease accounted for 83% of deaths in WHO's most recent country profile, and 12.47% of the population was aged 65 or over in 2025.
What Sets a World-Class Injectable Manufacturer in Sri Lanka Apart
The first differentiator is sterile capability that survives inspection rather than a general plant with a filling line bolted on. Injectables bypass every natural barrier the body has, so aseptic process design, ISO Class 5 filling under unidirectional airflow, validated terminal sterilisation or filtration, media fills, container-closure integrity testing, endotoxin control by LAL and a documented contamination-control strategy are the product, not refinements to it. Farbe Firma operates its Gujarat facility to WHO-GMP standards with ISO Class 5 aseptic core areas, routine environmental monitoring and full analytical release. That matters more in Sri Lanka than in most markets, because since the start of 2025 the NMRA has narrowed foreign site eligibility to PIC/S, EU GMP, WHO-prequalified and WHO-inspected plants, with everything else routed through a Manufacturing Peer Review Committee. Site standing is now assessed before the product is.
The second differentiator is knowing exactly where the Sri Lankan pathway costs more than expected. Registration is granted under the NMRA Act No. 5 of 2015 and the GL-021 Registration of Medicines Guideline, is valid five years, and for a first-time foreign manufacturer usually begins as provisional registration capped at two years. Gazette 2452/39 of 4 September 2025 redenominated fees in US dollars: a foreign new product costs US$750 with US$400 for the full five-year certificate, and foreign manufacturing premises approval US$2,000. Screening outcomes are notified within 28 working days. The multiplier that catches first-time filers is in GL-021 itself, which requires a separate dossier for each strength and for each container-closure system, so one molecule in three strengths across ampoule, vial and prefilled syringe is nine dossiers, nine fees and nine certificates. And price sits inside the registration decision, not beside it: sections 43(2)(b) and 45(3) of the Act direct the evaluation committee to weigh quality, efficacy, safety, need and cost with pharmacoeconomic analysis where necessary, section 60(1)(b) permits refusal on other relevant factors, and every application must state the intended maximum retail price and how it was derived.
Quality Systems Behind Every Batch We Ship to Sri Lanka
Every Farbe Firma injectable batch destined for Sri Lanka is released only after the full analytical stack is complete and reviewed. Identity, assay and related substances are determined by validated HPLC or GC methods against USP, BP, IP or EP monographs; water content by Karl Fischer where the presentation is lyophilised; sterility by membrane filtration or direct inoculation; bacterial endotoxins by LAL; and particulate matter, pH, osmolality, fill volume and container-closure integrity to compendial limits. Batch records, deviation reports and out-of-specification investigations are reviewed by qualified persons before release, and a retained sample of every batch is held for the full shelf life. That package is also the evidence base the National Medicines Quality Assurance Laboratory works from when it draws samples from an incoming consignment, so consistency between our certificate of analysis and the retest result is a commercial issue as much as a technical one.
Behind release testing sits the quality architecture that makes those results meaningful. Stability runs on three batches under long-term, intermediate and accelerated conditions per ICH Q1A, with photostability per ICH Q1B, and for Sri Lanka we generate long-term data at 30 °C and 75% relative humidity — the Climatic Zone IVb condition that a hot, humid maritime climate demands and that reviewers expect to see justified rather than assumed. Where a presentation exists that tolerates ambient storage, it is worth specifying: NMRA-referred consignments already clear more slowly than the national average, at a median of 74 hours 58 minutes by sea against 51 hours 32 minutes overall and 54 hours 55 minutes by air against 28 hours 12 minutes, and NMRA referrals account for 16.2% of all air import declarations. Every extra hour on a chilled pallet at Colombo is a risk that a thermostable presentation simply removes.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Sri Lanka for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at its WHO-GMP certified facility in Gujarat, India, and exports to over 30 countries. The portfolio spans anti-infectives, antimalarials, analgesics, anaesthetics and muscle relaxants, cardiovascular and emergency medicines, oncology support, obstetric and life-saving products, in dry-powder vials, liquid ampoules, lyophilised presentations and small-volume parenterals. For Sri Lanka that maps directly onto the ceftriaxone and injectable anti-infective lines that carry the country's septicaemia and leptospirosis load, the crystalloids and emergency medicines a record dengue season consumes, the oxytocin, tranexamic acid and magnesium sulphate behind 200,000 institutional deliveries a year, and the anaesthesia, analgesic and oncology-support lines that keep teaching, provincial, district general and base hospitals running.
Our CDMO services scale from a single distributor's launch portfolio to full tender volumes. Contract and third-party manufacturing runs under the customer's brand with technology transfer, artwork development and dossiers compiled in CTD or ACTD format. Sri Lankan artwork has become genuinely demanding and we build it properly the first time. The label body is in English, with the generic name in Sinhala and Tamil on the carton — a requirement GL-006 expressly does not impose on injections that require professional healthcare staff to administer. Ampoules and vials of 10 mL or less need six data elements plus route of administration. Sterility and apyrogenicity statements, benzyl alcohol declarations and storage wording drawn from the NMRA's own vocabulary all apply. Since 1 April 2026 every commercial pack released to market must carry the words “NMRA Registered Product” together with the approved maximum retail price, printed or on a sticker, with a June 2026 amendment permitting either peelable or non-peelable labels; and a product-specific QR code or 2D DataMatrix carrying product code, lot number, manufacturing and expiry dates and serial number is required following the close of the grace period on 30 June 2026.
Buyers stay with Farbe Firma because we are straightforward about what the Sri Lankan route actually involves. Product must be registered and imported through a locally established authorisation holder with an import licence under the GL-002 Import Control Guideline, and from 1 April 2026 every marketing authorisation holder of an imported product must file quarterly consignment data on the NMRA's Excel template. Public volume runs through the State Pharmaceuticals Corporation and the Medical Supplies Division, where the medical supplies budget grew from LKR 70.8 billion to LKR 176.5 billion between 2022 and 2023, and 2025 SPC orders reached LKR 90 billion plus a further LKR 20 billion. That is real money, but the terms are firm: a 10% performance bond on award, and clause 16.3 of SPC's 2026 tender conditions states plainly that any request for a price increment arising from rupee depreciation will not be accepted. Set against that, the rupee fell about 8% in the first half of 2026 to a four-year low on 21 May, the last general price revision was a 16% cut in 2023, and on 22 April 2026 the Sri Lanka Chamber of the Pharmaceutical Industry warned the country was on the brink of a crippling medicine shortage. NMRA opened an application-based MRP revision window on 8 July 2026 for currency movement above 5%, but any approved increase applies only to consignments imported after approval. Price your first Sri Lankan contract on that basis, not on spot FX, and confirm current status with NMRA before you file.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer that can supply Sri Lanka?
Yes. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, with ISO Class 5 aseptic filling areas, more than 100 injectable products and exports to over 30 countries. For Sri Lanka we supply the documentation set the NMRA expects: a WHO-format Certificate of Pharmaceutical Product, a valid GMP certificate, the site master file, batch certificates of analysis against USP, BP, IP or EP monographs, ICH Q1A stability with Climatic Zone IVb long-term data at 30 °C and 75% relative humidity, and a CTD or ACTD dossier with English artwork built to the GL-006 labelling guideline. One point we raise early rather than late: since 1 January 2025 the NMRA accepts foreign manufacturing-site applications from PIC/S-approved, EU GMP-approved, WHO-prequalified or WHO-inspected sites as of right, and considers other sites case by case through the CEO and the Manufacturing Peer Review Committee. We work with your regulatory team to settle site standing before the product dossier is compiled.
How long does it take to register an injectable in Sri Lanka, and what does it cost?
Registration is granted under the NMRA Act No. 5 of 2015 and the GL-021 guideline, runs for five years, and typically starts as provisional registration limited to two years for a first-time foreign manufacturer. Screening outcomes are notified within 28 working days; the NMRA does not publish an end-to-end statutory clock for the standard route, so plan conservatively. The reliance route is different and much faster: the GL-025 Reliance Practices guideline, effective 31 January 2025, provides 90-day processing for qualifying products, and Sri Lanka has participated in the WHO Collaborative Registration Procedure since 2017 on the same 90-day basis. On fees, Gazette 2452/39 of 4 September 2025 redenominated the schedule in US dollars: US$750 for a foreign new product, US$400 for the full five-year certificate, US$2,000 for foreign manufacturing premises approval, and US$15,000 plus airfare and visas for a foreign GMP inspection of a SAARC applicant. Remember that GL-021 requires a separate dossier per strength and per container-closure system, which multiplies both fees and timelines.
Do we need a local partner in Sri Lanka, or can we register and import directly?
A locally established partner is required in practice. The marketing authorisation and the import licence sit with a Sri Lankan entity operating under the GL-002 Import Control Guideline, and that entity carries the ongoing obligations — including the quarterly consignment data return on the NMRA's Excel template, mandatory for every marketing authorisation holder of an imported product since 1 April 2026, and responsibility for the “NMRA Registered Product” and maximum retail price markings on each commercial pack. Farbe Firma supplies the manufacturer-side package: the Certificate of Pharmaceutical Product, GMP certificate, site master file, stability and analytical data, letters of authorisation and artwork files. Your Sri Lankan partner holds the licence, lodges the dossier, files the price application and manages release. For public-sector volume the same partner is normally your route into State Pharmaceuticals Corporation and Medical Supplies Division tendering.
Which injectables are in strongest demand in Sri Lanka?
Injectable anti-infectives lead. Septicaemia recorded 18,955 admissions and 8,762 deaths at a 46.2% case-fatality rate in 2023, and leptospirosis killed 203 people that year — more than three times the dengue toll — which puts ceftriaxone and the broader parenteral antibiotic range at the centre of demand. Fluid resuscitation follows: 2026 is a record dengue year with 56,422 cases by 1 July, already above the whole of 2025, and dengue management is largely a crystalloid and monitoring problem. Obstetric injectables come next, with roughly 200,000 institutional deliveries a year at a caesarean rate near 42%, which translates into oxytocin, tranexamic acid, magnesium sulphate and the associated anaesthesia lines. Beyond that, snakebite drove 29,975 admissions in 2023 against no domestic antivenom production and an antivenom bill of about US$6.3 million a year, and an ageing population — 12.47% aged 65 or over in 2025 — with non-communicable disease at 83% of deaths sustains cardiovascular, oncology-support and emergency lines.
What are the real pricing, cost and logistics constraints on shipping injectables to Sri Lanka?
The tariff position is favourable and rarely the problem: registered medicines enter free of general customs duty and exempt from VAT, PAL and SSCL, and remained exempt when standard VAT rose to 20.5% on 1 July 2026. The binding constraint is price regulation. Under Gazette 2446/34 of 21 July 2025 and GL-033 v1.1, the maximum retail price is CIF plus duties and taxes plus a blended supply-chain and trade margin sliding from 75% at CIF under LKR 40 to 45% at CIF of LKR 6,500 or more, and the NMRA verifies the declared CIF against India's own NPPA prices as well as Bangladesh, Pakistan and international references. Where the calculated MRP exceeds a gazetted ceiling price, the ceiling applies. Currency movement above 5% is the only revision trigger, revisions are applied for company by company and apply only to consignments imported after approval, and SPC's 2026 tender conditions refuse FX-driven price increments outright. On logistics, Colombo is well served but NMRA-referred consignments clear at a median of 74 hours 58 minutes by sea against 51 hours 32 minutes overall, so build the referral into your lead time and prefer thermostable presentations where a validated option exists.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments